Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2006

01-01-2006

Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer

Authors: Karolina Przybylowska, Anita Kluczna, Marek Zadrozny, Tadeusz Krawczyk, Andrzej Kulig, Jan Rykala, Agnieszka Kolacinska, Zbigniew Morawiec, Jozef Drzewoski, Janusz Blasiak

Published in: Breast Cancer Research and Treatment | Issue 1/2006

Login to get access
Metadata
Title
Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer
Authors
Karolina Przybylowska
Anita Kluczna
Marek Zadrozny
Tadeusz Krawczyk
Andrzej Kulig
Jan Rykala
Agnieszka Kolacinska
Zbigniew Morawiec
Jozef Drzewoski
Janusz Blasiak
Publication date
01-01-2006
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-9042-6

Other articles of this Issue 1/2006

Breast Cancer Research and Treatment 1/2006 Go to the issue

OriginalPaper

Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer

Epidemiology

Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype–phenotype correlations

Clinical trial

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

OriginalPaper

Activation of vascular endothelial growth factor (VEGF) by the ER-α variant, ERΔ3

OriginalPaper

Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies

OriginalPaper

Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits